Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology - Takeaways - MDSpire

Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology

  • By

  • Matthias Augustin

  • H. Chih-ho Hong

  • Tiago Torres

  • Naiem T. Issa

  • July 7, 2026

  • 0 min

Share

  • 1

    Significant differences in clinical trial designs for biologics hinder direct efficacy comparisons for moderate-to-severe atopic dermatitis.

  • 2

    Matching-adjusted indirect comparisons (MAICs) utilize individual patient data to adjust for differences in patient and disease characteristics.

  • 3

    Three MAICs indicate comparable long-term efficacy among tralokinumab, dupilumab, and lebrikizumab for treating moderate-to-severe atopic dermatitis.

  • 4

    Differences in baseline disease severity across trials can significantly impact efficacy outcomes in atopic dermatitis randomized controlled trials.

  • 5

    Long-term data for nemolizumab is not yet published, leading to its exclusion from the analysis of biologic treatments for atopic dermatitis.

Original Source(s)

Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology

  • by Matthias Augustin, H. Chih-ho Hong, Tiago Torres, Naiem T. Issa

  • July 7, 2026

Related Content

Is hidradenitis suppurativa more an autoinfection than pure autoinflammation?

Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis

Skin malformation assessment by triple wavelength imaging